Changes from imatinib mesylate to second generation tyrosine kinase inhibitors improve renal impairment with imatinib mesylate in chronic myelogenous leukemia.
about
Changes from imatinib mesylate to second generation tyrosine kinase inhibitors improve renal impairment with imatinib mesylate in chronic myelogenous leukemia.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh-hant
name
Changes from imatinib mesylate ...... chronic myelogenous leukemia.
@en
Changes from imatinib mesylate ...... chronic myelogenous leukemia.
@nl
type
label
Changes from imatinib mesylate ...... chronic myelogenous leukemia.
@en
Changes from imatinib mesylate ...... chronic myelogenous leukemia.
@nl
prefLabel
Changes from imatinib mesylate ...... chronic myelogenous leukemia.
@en
Changes from imatinib mesylate ...... chronic myelogenous leukemia.
@nl
P2093
P2860
P1476
Changes from imatinib mesylate ...... chronic myelogenous leukemia.
@en
P2093
Akihisa Hino
Hiroaki Masaie
Hitoshi Yoshida
Jun Ishikawa
Midori Koike
Ryota Minami
P2860
P2888
P304
P356
10.1007/S12185-016-2071-6
P577
2016-07-26T00:00:00Z